Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$824.48 USD
+7.83 (0.96%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $824.95 +0.47 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$824.48 USD
+7.83 (0.96%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $824.95 +0.47 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
by Zacks Equity Research
Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.
Here's Why Geron (GERN) is a Good Stock to Invest in Now
by Zacks Equity Research
Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.
Indivor's Opioid Use Disorder Drug Meets Primary Endpoint
by Zacks Equity Research
Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.
AveXis (AVXS) Jumps: Stock Rises 7.1%
by Zacks Equity Research
AveXis, Inc.(AVXS) was a big mover last session, as the company saw its shares rise over 7% on the day.
Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) shares rose over 5% in the last trading session.
Novartis Migraine Drug Accepted, AMD Positive in Phase III
by Zacks Equity Research
Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
by Tirthankar Chakraborty
IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.
Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
by Zacks Equity Research
Vanda Pharmaceuticals Inc. (VNDA) shares rose over 8% in the last trading session.
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
by Arpita Dutt
Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia
Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Merrimack Completes Enrollment in Phase II Study for MM-141
by Zacks Equity Research
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.
CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day
A Lazy, Unfocused Summer Is Here: Global Week Ahead
by John Blank
A lazy, unfocused summer is here. Yet that sentiment might be bullish stocks. No new news may be good news -- in this upward trending market -- driven by momentum, mostly.
GlaxoSmithKline's Benlysta Positive in Continuation Trial
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley
by Zacks Equity Research
Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley
GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
by Zacks Equity Research
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.
5 Stocks with Solid Sales Growth Catching Eyeballs
by Zacks Equity Research
Sales growth is an important indicator of a company's health and ability to sustain its business. It offers investors an insight into product demand and pricing power.
Lilly Plans New Outcomes Study to Expand Jardiance Label
by Zacks Equity Research
Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.
J&J Announces EU Regulatory Approval for Actelion Deal
by Zacks Equity Research
Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.
Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.